The routine clinical use of pharmacogenetic tests: what it will require?

Mafalda Dias, Michael Sorich, Andrew Rowland, Michael Wiese, Ross McKinnon

    Research output: Contribution to journalReview articlepeer-review

    16 Citations (Scopus)


    Pharmacogenetic testing aims to personalize drug therapy with a view to optimising drug efficacy and minimise toxicity. However, despite the potential benefits, pharmacogenetic testing is mostly confined to specialised medical areas, laboratories and centres. Widespread integration into routine clinical practice has been limited by a complex set of issues including regulatory and reimbursement frameworks, evidence of clinical utility and clinician perspectives, practices and education. Here we assess the current barriers to widespread clinical uptake and identify the key issue necessary to address to accelerate routine testing.

    Original languageEnglish
    Pages (from-to)1544-1550
    Number of pages7
    Issue number8
    Early online date2017
    Publication statusPublished - Aug 2017


    • biomarkers
    • clinical uptake
    • diagnostic tests
    • personalized medicine


    Dive into the research topics of 'The routine clinical use of pharmacogenetic tests: what it will require?'. Together they form a unique fingerprint.

    Cite this